Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (November 2025)
24 slides from Immutep's shareholder meeting presentation, Nov 27, 2025
Slide 1: Annual General Meeting 2025
Annual General Meeting 2025 For personal use only (ASX:IMM, NASDAQ:IMMP) Empowering the immune system to fight cancer and autoimmune disease 1
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanat
Slide 3: Agenda
For personal use only Agenda • Overview of Immutep • Highlights • Efti Program • IMP761 Program • Summary 3
Slide 4: Overview of Immutep
4 For personal use only Overview of Immutep
Slide 5: Immutep Highlights
Immutep Highlights For personal use only Four clinical-stage assets designed to safely empower patients’ immune systems to fight cancer A leader in LAG-3 and autoimmune diseases through the MHC Class II & LAG-3 pathways, including first-in-class immunotherapy immunotherapies eftilagimod alfa (efti)
Slide 6: Deep Clinical Pipeline in Oncology & Autoimmune Diseases
Deep Clinical Pipeline in Oncology & Autoimmune Diseases For personal use only Information current as of October 2025. 1. Investigator-initiated trial that Immutep has no control over. 2. Three trials for IMP731 were conducted by GSK (two Phase I studies in healthy volunteers and psoriasis and a Pha
Slide 7: Highlights
7 For personal use only Highlights
Slide 8: Immutep's Key Value Driver: TACTI-004 in 1L NSCLC
For personal use only Immutep’s Key Value Driver TACTI-004 (KEYNOTE-F91) in First Line Non-Small Cell Lung Cancer (1L NSCLC) • Lung cancer is the leading cause of cancer death and non-small cell lung cancer (NSCLC) comprises 80 to 85% of all lung cancers1,2 • ~2.0 million NSCLC diagnoses annually •
Slide 9: FY25 Clinical Milestones in TACTI-004 Phase III in 1L NSCLC
FY25 Clinical Milestones in TACTI-004 Phase III in 1L NSCLC For personal use only • June 2024 - Third collaboration & supply agreement with MSD Non-small cell for TACTI-004 (KEYNOTE-F91) announced lung cancer • March 2025 - Successful dosing of first patient at Calvary TACTI-004 Mater Newcastle Hosp
Slide 10: Efti's Key Attributes & Encouraging Key Opinion Leader Feedback
Efti’s Key Attributes & Encouraging Key Opinion Leader Feedback For personal use only Efti Key Attributes KOL Feedback on Efti & 1L NSCLC Phase III1,2,3 Ø Real innovation – Efti is a first-in-class asset unlike any Ø Robust fundament in NSCLC – Positive on efti driving in the immunotherapy landscape
Slide 11: TACTI-004/KEYNOTE-F91 Phase III Trial in 1L NSCLC
TACTI-004/KEYNOTE-F91 Phase III Trial in 1L NSCLC For personal use only Third collaboration & supply agreement with MSD - who jointly designed registrational TACTI-004 trial with Immutep - announced in June 2024: • 1:1 randomized, double-blind trial enrolling ~756 patients in +150 sites across +25 c
Slide 12: TACTI-004 Milestones and Multiple Potential Paths to Success
TACTI-004 Milestones and Multiple Potential Paths to Success For personal use only TACTI-004/KN-F91 Milestones 1st Patient in: Recruitment for Futility Last Patient Interim 25 March 2025 Futility Analysis Analysis In (LPI) Analysis: PFS* Q2’25 Q3’25 YE’25 Q1’26 Q2’26 Q3’26 YE’26 Q1’27 Q2’27 * Potent
Slide 13: Global Phase III Landscape for Advanced/Metastatic 1L NSCLC
Global Phase III Landscape for Advanced/Metastatic 1L NSCLC For personal use only Companies that have a CTCSA with MSD for No PD-L1 Low PD-L1 High PD-L1 Non- % of 1L NSCLC Squamous Phase III trials in advanced/metastatic 1L NSCLC1 TPS <1% TPS 1-49% TPS >50% Squamous Population % of 1L NSCLC patient
Slide 14: Potential Blockbuster Commercial Opportunity
Potential Blockbuster Commercial Opportunity For personal use only If TACTI-004 is successful it presents a potential multi-billion US$ opportunity 1L NSCLC for efti as it will be a safe add-on to KEYTRUDA & chemo in 1L NSCLC: • KEYTRUDA has revolutionized treatment landscape and MSD captures 7 to 8
Slide 15: Efti's Potential to Extend IP for PD-1 Inhibitors
Efti’s Potential to Extend IP for PD-1 Inhibitors For personal use only 2024 Sales of Anti-PD-(L)1 Therapies ($ Billions) 30 29.5 25 • Efti’s comprehensive patent portfolio provides an opportunity to enhance and substantially extend 20 established or new PD-(L)1 franchises 15 • Two leading PD-1 inhi
Slide 16: FY25 Clinical Milestones in Additional Efti Clinical Trials
FY25 Clinical Milestones in Additional Efti Clinical Trials For personal use only Non-small cell Soft tissue Head & neck squamous Metastatic lung cancer sarcoma cell carcinoma breast cancer INSIGHT-003 EFTISARC-NEO TACTI-003 AIPAC-003 INSIGHT-003 is evaluating efti in EFTISARC-NEO is evaluating TACT
Slide 17: INSIGHT-003: Strong Efficacy Across All PD-L1 Levels
INSIGHT-003: Strong Efficacy Across All PD-L1 Levels For personal use only Benchmarking Efti + KEYTRUDA + Chemo1 in non-squamous 1L NSCLC to KEYTRUDA + Chemo2 Objective Response Rate Progression-Free Survival Overall Survival 75.0 14 35 32.9 75 12.7 70 68.0 12 30 65 62.1 60 25 54.5 10 9.0 Time (mont
Slide 18: INSIGHT-003 Case Study: Patient with PD-L1 TPS 0%
INSIGHT-003 Case Study: Patient with PD-L1 TPS 0% For personal use only Baseline After 1 Year of Therapy September 2024 September 2025 Case study of a 75-year-old male TL1 TL1 with partial response (PR): Lung: Lung: 27 mm 7 mm • PD-L1 TPS 0%, no actionable genetic alterations • TTF1 pos. Adeno-Carci
Slide 19: Primary Endpoint Met in Phase II Trial in Soft Tissue Sarcoma
Primary Endpoint Met in Phase II Trial in Soft Tissue Sarcoma For personal use only ESMO Congress 2025 – Proffered Paper Oral Presentation Neoadjuvant efti + KEYTRUDA + radiotherapy met primary endpoint with median 51.5% Hyalinization/Fibrosis Viable Tumour Cells tumour hyalinization/fibrosis (p<0.0
Slide 20: First-in-Human Phase I Trial of IMP761
First-in-Human Phase I Trial of IMP761 World-class research institute, CHDR, appointed to conduct first-in-human study For personal use only Overview / Key Milestones: • Placebo-controlled, double-blind Phase I • Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, conducting study in h
Slide 21: FY25 Financial Summary
FY25 Financial Summary For personal use only FY25 FY24 • Strong cash position of approx. A$109.9 million as of 30 Sept 2025 (includes short term deposits) Revenue and other income A$10.3M A$7.8M • Total revenue and other income were A$10.3 million in FY25 compared to A$7.8 million in FY24 G&A Expens
Slide 22: Immutep Enters the S&P/ASX & Patent Protection
Immutep Enters the S&P/ASX 300 & Patent Protection For personal use only S&P/ASX300 Robust Intellectual Property Protection • Recognising Immutep’s considerable growth Efti over the years as a listed company, the Company was added to the S&P/ASX 300 • Seven patents were granted in FY24: index follow
Slide 23: Upcoming Milestones
Upcoming Milestones For personal use only • Non-Small Cell Lung Cancer – TACTI-004 futility analysis in Q1 2026 • Head and Neck Squamous Cell Carcinoma – Ongoing evaluation of potential options for collaborative clinical development & paths for accelerated approval in 1L HNSCC CPS <1 • Metastatic Br
Slide 24: Thank You
24 For personal use only Thank You